What changed in FDA's 2026 clinical decision support guidance?

FDA's revised CDS guidance (6 January 2026) widens enforcement discretion for single-recommendation tools. What it covers, what it leaves out, and its silence on AI.

  • US

1The revised guidance is final, was issued without a comment period on 6 January 2026 and reissued on 29 January 2026, and supersedes the 2022 CDS guidance.

2A tool that presents a single clinically appropriate recommendation can now fall under enforcement discretion; the 2022 version required a list of options.

3The guidance covers software for health care professionals. It sets no new policy for patient-facing tools or symptom checkers.

4Software that analyses a medical image itself to generate findings remains a device.

Limits of this page. FDA's own PDF text was not machine-readable when we reviewed it. The description of what changed comes from law-firm summaries (Covington, DLA Piper, Cooley), not from the guidance text. One secondary source gives a publication date of 11 March 2026; law firms and FDA's page support 6 January.

What is the FDA clinical decision support guidance?

It is FDA’s statement of which decision-support software it treats as a medical device and which it does not. The revised version was issued on 6 January 2026 as a final guidance without a comment period, reissued on 29 January 2026, and replaces the 2022 version.

What changed in the 2026 revision?

The main change is enforcement discretion for tools that give a single clinically appropriate recommendation. The 2022 guidance expected a list of options. The statutory criteria for non-device CDS did not change, and the revision keeps the automation-bias analysis, now discussed under the fourth criterion.

Topic 2022 guidance January 2026 revision
Single recommendation Expected a list of options Enforcement discretion for one clinically appropriate option
Risk scores Treated cautiously Discussed with examples; not strictly barred
Audience Health care professionals Health care professionals only
Patient-facing tools Not covered Still not covered
AI No specific policy No new AI-specific policy found in summaries

What is still a device?

Software that analyses a medical image or signal itself to generate findings remains a device. Software that analyses a radiologist’s findings to draft a summary and recommendation may fall under enforcement discretion, according to one law-firm reading. Treat that as a lead for counsel, not a conclusion.

What does this mean for teams building or buying healthcare AI?

It loosens one federal pressure to produce validation evidence. Buyers will still ask for it, because contracts, accreditation guidance and state law do not depend on this guidance. See the Joint Commission and CHAI guidance and the HTI-5 final rule.

What did we not verify?

We did not read FDA’s guidance text, only summaries of it. Check the primary document before citing any detail, and ask counsel how the guidance applies to a specific function.

Frequently asked questions

Does FDA's 2026 CDS guidance cover AI and large language models?

Not expressly. The summaries we reviewed say the guidance does not set a new approach for AI. It addresses clinician-facing decision support software generally. Whether a generative-AI feature is a device still depends on its function and claims, which is a question for regulatory counsel.

Are patient-facing chatbots covered by the CDS guidance?

No. The guidance covers software for health care professionals. It sets no new policy for patient-facing tools or symptom checkers, so those remain subject to FDA's device framework and to state law.

Is an AI scribe regulated as a device under this guidance?

Commentary from 2026 describes ambient scribes as administrative tools, not FDA-regulated devices, but notes this may change if their clinical functions expand. The CDS guidance itself does not mention scribes in the summaries we reviewed.

Sources

  1. Clinical Decision Support Software: guidance for industry and FDA staffU.S. Food and Drug Administration · 2026-01-29
  2. 5 key takeaways from FDA's revised clinical decision support software guidanceCovington · 2026-01
  3. FDA updates its clinical decision support and general wellness guidances: key pointsDLA Piper · 2026-01
  4. Automation bias and clinical practice: FDA makes incremental updates to the CDS software guidanceCooley · 2026-01-20

Found something out of date? Write to hello@precision.example and we will fix it.

Written and reviewed byPrecision research teamHealthcare AI evaluation research